Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B5af6c7495956998b8f5042db7249835c> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B5af6c7495956998b8f5042db7249835c NCIT_P378 "NCI" @default.
- B5af6c7495956998b8f5042db7249835c type Axiom @default.
- B5af6c7495956998b8f5042db7249835c annotatedProperty IAO_0000115 @default.
- B5af6c7495956998b8f5042db7249835c annotatedSource NCIT_C179627 @default.
- B5af6c7495956998b8f5042db7249835c annotatedTarget "An orally bioavailable, selective pan-tropomyosin-related-kinase (tyrosine receptor kinase; TRK) inhibitor, with potential antineoplastic activity. Upon oral administration, pan-TRK inhibitor ICP-723 specifically targets and binds to TRK, TRK mutations and fusion proteins containing sequences from neurotrophic tyrosine receptor kinase (NTRK) types 1 (NTRK1; TrkA), 2 (NTRK2; TrkB), and 3 (NTRK3; TrkC). This inhibits neurotrophin-TRK interaction and TRK activation, thereby preventing the activation of downstream signaling pathways and resulting in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress TRK and/or express NTRK fusion proteins. TRK, a family of receptor tyrosine kinases (RTKs) activated by neurotrophins, is encoded by NTRK family genes. The expression of either mutated forms of, or fusion proteins involving, NTRK family members results in uncontrolled TRK signaling, which plays an important role in tumor cell growth, survival, invasion and treatment resistance." @default.